

Table 2: Proportion of Cancers Identified in AI High-Risk Tiers

Note: AI tools are evolving rapidly, with new AI tools, additional FDA clearances, and ongoing acquisitions that may change the commercial landscape.

Study (Cohort)	Paper and Year	High-Risk Tier (% of Population)	% Women with Cancer Identified	AI Software	Validation
Mass General Brigham	Lehman et al. (2022)	Top 50.0%	75.2%	Mirai	2D
Mass General Brigham	Lamb et al. (2026)	Top 22.7%	49.1%	Mirai	2D
Multi-Institutional	Yala et al. (2022)	Top 10.0%	41.5%	Mirai	2D
NHSBSP (UK)	Rothwell et al. (2026)	Top 14.0%	~40.0%	Mirai (DL-1)	2D
KARMA (Sweden)	Eriksson et al. (2026)	Top 10.0%	33.0%	Ensemble AI	2D
CSAW-S (Sweden)	Liu et al. (2024)	Top 8.0%	33.0%	AI SmartDensity	2D
MGH (USA)	Yala et al. (2019)	Top 10.0%	31.2%	Hybrid DL (Mirai)	2D
Olmsted (USA)	Eriksson et al. (2026)	Top 10.0%	30.0%	Ensemble AI	2D
EMBED (USA)	Eriksson et al. (2026)	Top 10.0%	30.0%	Ensemble AI	2D
Kaiser Permanente	Arasu et al. (2023)	Top 10.0%	24% – 28%	Mirai, MammoScreen, ProFound AI Globally Aware Multiple Instance Classifier	2D
NHSBSP (UK)	Rothwell et al. (2026)	Top 4.0%	~20.0%	Mirai (DL-1)	2D
KARMA (Sweden)	Eriksson et al. (2022)	Top 6.3% Top 12%	20.0% 59%	ProFound AI Risk	3D/DBT ©DenseBreast-info.org Revised July 2026

2D = full-field digital mammography; 3D/DBT = digital breast tomosynthesis

Not detailed in the above table, Clarity Breast, based on the Mirai open-source toolkit, is currently the only FDA-cleared AI tool for breast cancer risk prediction.